


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): A compound represented by the general formula (I):



wherein,

R^1 and R^2 may be the same or different and each represents an aryl group, heteroaryl group, aryl group substituted with 1 to 3 groups selected from Substituent group α , or heteroaryl group substituted with 1 to 3 groups selected from Substituent group α ;

R^3 represents any one of the following groups:

$-\text{CO}-\text{R}^4$,

$-\text{CO}-\text{O}-\text{R}^4$,

-CO-NH-R^4 ,
 $\text{-CO-CH}_2\text{-N(R}^a\text{)R}^b$,
 $\text{-(CH}_2\text{)}_m\text{-CO-R}^5$,
 $\text{-(CH}_2\text{)}_m\text{-R}^5$,
 $\text{-CO-NH-CO-N(R}^a\text{)R}^b$,
 $\text{-CO-NH-SO}_2\text{-N(R}^a\text{)R}^b$,
 ~~$\text{-CO-NH-CO-(CH}_2\text{)}_p\text{-N(R}^a\text{)R}^b$~~ , $\text{-CO-NH-CO-(CH}_2\text{)}_m\text{-N(R}^a\text{)R}^b$, and
 -CO-NH_2 ;

R^4 represents a lower alkyl group, cycloalkyl group, cycloalkyl group substituted with 1 to 3 groups selected from Substituent group α , lower alkenyl group, lower alkynyl group, halogeno lower alkyl group, hydroxy lower alkyl group, lower alkoxyalkyl group, lower aliphatic acyloxyalkyl group or lower alkoxycarbonylalkyl group;

R^5 represents a hydroxyl group, a group -OR^4 , or a group $\text{-N(R}^a\text{)R}^b$;

R^a and R^b may be the same or different and each represents a hydrogen atom, hydroxyl group, lower alkoxy group, hydroxy lower alkoxy group, hydroxy lower alkoxyalkyl group, lower alkoxy lower alkoxyalkyl group, cyano lower alkyl group, cyano lower alkoxyalkyl group, carboxy lower alkyl group, carboxy lower alkoxyalkyl group, lower alkoxycarbonyl lower alkoxyalkyl group, carbamoyl lower alkyl group, carbamoyl lower alkoxyalkyl group,

lower aliphatic acylamino lower alkyl group, lower aliphatic acylamino lower alkoxyalkyl group, lower alkylsulfonylamino lower alkyl group, lower alkylsulfonylamino lower alkoxyalkyl group, (N-hydroxy-N-methylcarbamoyl) lower alkyl group, (N-hydroxy-N-methylcarbamoyl) lower alkoxyalkyl group, (N-lower alkoxy-N-methylcarbamoyl) lower alkyl group, (N-lower alkoxy-N-methylcarbamoyl) lower alkoxyalkyl group or R⁴, or together, including the nitrogen atom to which they are attached, represent a nitrogen-containing heterocyclic group or nitrogen-containing heterocyclic group substituted with 1 to 3 groups selected from Substituent group α ;

m represents an integer of 1 to 6;

A represents a methylene group, carbonyl group or sulfonyl group;

B represents a single bond, C₁-C₄ alkylene group or C₂-C₄ alkenylene group;

D represents an oxygen atom or methylene group;

E represents a C₁-C₄ alkylene group or C₂-C₄ alkenylene group;

n represents an integer of 1 to 3; and,

Substituent group α represents a group of substituents consisting of halogen atoms, lower alkyl groups, hydroxy lower

alkyl groups, halogeno lower alkyl groups, carboxy lower alkyl groups, lower alkoxy groups, hydroxy lower alkoxy groups, hydroxy lower alkoxyalkyl groups, lower alkoxy carbonyl groups, carboxyl groups, hydroxyl groups, lower aliphatic acyl groups, lower aliphatic acylamino groups, (N-hydroxy-N-methylcarbamoyl) lower alkyl groups, (N-lower alkoxy-N-methylcarbamoyl) lower alkyl groups, hydroxy lower aliphatic acylamino groups, amino groups, carbamoyl groups and cyano groups, or a pharmacologically acceptable salt or other derivative thereof.

Claims 2-20 (Canceled).

Claim 21 (Currently Amended): The compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 18~~ claim 1, wherein one of R^a and R^b represents a hydrogen atom, lower alkyl group, hydroxyl group or lower alkoxy group and the other represents a hydroxy lower alkyl group, hydroxy lower alkoxyalkyl group, carboxy lower alkyl group, carboxy lower alkoxyalkyl group, lower alkoxy carbonyl lower alkyl group or lower alkoxy carbonyl lower alkoxyalkyl group, or R^a and R^b together, including the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group or nitrogen-

containing heterocyclic group substituted with 1 to 3 groups selected from Substituent group α .

Claim 22 (Currently Amended): The compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 18~~ claim 1, wherein $-N(R^a)R^b$ is N-(3-hydroxypropyl)-N-methylamino, N-(4-hydroxybutyl)-N-methylamino, N-(5-hydroxypentyl)-N-methylamino, N-(6-hydroxyhexyl)-N-methylamino, N-[2-(2-hydroxyethoxy)ethyl]-N-methylamino, N-(2-hydroxyethyl)-N-methoxyamino, N-(3-carboxypropyl)-N-methylamino, 2-(3-hydroxypropyl)pyrrolidino, 4-hydroxymethylpiperidino, 4-(2-hydroxyethyl)piperidino, 4-(3-hydroxypropyl)piperidino, 4-(2-hydroxyethoxy)piperidino, 4-(hydroxyacetamido)piperidino, 4-(2-hydroxyethoxymethyl)piperidino or 4-(2-hydroxyethyl)piperazino.

Claim 23 (Canceled).

Claim 24 (Currently Amended): A pharmaceutical composition for the treatment or prophylaxis of diseases mediated by NK_1 , NK_2 and/or NK_3 receptors containing, ~~as an active ingredient,~~ an effective amount of a compound or pharmacologically acceptable

salt thereof according to ~~any one of claims 1 to 22~~ claim 1, in a pharmaceutically acceptable carrier.

Claim 25 (Currently Amended): A pharmaceutical composition for the prophylaxis or treatment of respiratory diseases, allergic diseases and/or urinary incontinence containing, as an active ingredient, a compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 22~~ claim 1, in a pharmaceutically acceptable carrier.

Claim 26 (Currently Amended): A pharmaceutical composition for the prophylaxis or treatment of asthma, bronchitis, chronic obstructive lung disease, rhinitis and/or urinary incontinence containing, ~~as an active ingredient,~~ an effective amount of a compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 22~~ claim 1, in a pharmaceutically acceptable carrier.

Claim 27 (Currently Amended): A pharmaceutical composition for the prophylaxis or treatment of respiratory diseases containing, ~~as an active ingredient,~~ an effective amount of a compound or pharmacologically acceptable salt thereof to ~~any one~~

~~of claims 1 to 22~~ claim 1, in a pharmaceutically acceptable carrier.

Claim 28 (Currently Amended): A pharmaceutical composition for the prophylaxis or treatment of asthma, bronchitis and/or chronic obstructive lung disease containing, ~~as an active ingredient,~~ an effective amount of a compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 22~~ claim 1, in a pharmaceutically acceptable carrier.

Claim 29 (Currently Amended): The composition according to claim 27 ~~or claim 28~~ for pulmonary administration.

Claims 30-36 (Canceled).

Claim 37 (Currently Amended): A method for preventing or treating diseases mediated by NK₁, NK₂ and/or NK₃ receptors by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 22~~ claim 1 to a mammal.

Claim 38 (Currently Amended): A method for preventing or treating respiratory diseases, allergic diseases and/or urinary incontinence by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 22~~ claim 1 to a mammal.

Claim 39 (Currently Amended): A method for preventing or treating asthma, bronchitis, chronic obstructive lung disease, rhinitis and/or urinary incontinence by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 22~~ claim 1 to a mammal.

Claim 40 (Currently Amended): A method for preventing or treating respiratory diseases by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 22~~ claim 1 to a mammal.

Claim 41 (Currently Amended): A method for preventing or treating asthma, bronchitis and/or chronic obstructive lung disease by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to ~~any one of claims 1 to 22~~ claim 1 to a mammal.

Claim 42 (Currently Amended): The method according to ~~any one of claims 39 to 40~~ claim 40, wherein a compound having the general formula (I) or pharmacologically acceptable salt thereof is administered by pulmonary administration.

Claim 43 (Currently Amended): The method according to ~~any one of claims 37 to 42~~ claim 37, wherein the mammal is a human.

Claim 44 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein

R¹ is an aryl group or an aryl group substituted with 1 to 3 groups selected from substituent group α ,

R² is an aryl group substituted with 1 to 3 groups selected from substituent group α ,

A is a methylene group or carbonyl group,

B is a single bond or C₁-C₄ alkylene group,

D is an oxygen atom or a methylene group and

E is a C₁-C₄ alkylene group and

wherein one of R^a and R^b represents a hydrogen atom, lower alkyl group, hydroxyl group or lower alkoxy group and the other represents a hydroxy lower alkyl group, hydroxy lower alkoxyalkyl

group, carboxy lower alkyl group, carboxy lower alkoxyalkyl group, lower alkoxy carbonyl lower alkyl group or lower alkoxy carbonyl lower alkoxyalkyl group, or R^a and R^b together, including the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group or nitrogen-containing heterocyclic group substituted with 1 to 3 groups selected from Substituent group α .

Claim 45 (New): The compound or pharmacologically acceptable salt thereof according to claim 44, wherein

R¹ is phenyl or phenyl substituted with 1 to 3 groups selected from substituent group α ,

R² is a phenyl group substituted with 1 or 2 halogen atoms and

wherein -N(R^a)R^b is N-(3-hydroxypropyl)-N-methylamino, N-(4-hydroxybutyl)-N-methylamino, N-(5-hydroxypentyl)-N-methylamino, N-(6-hydroxyhexyl)-N-methylamino, N-[2-(2-hydroxyethoxy)ethyl]-N-methylamino, N-(2-hydroxyethyl)-N-methoxyamino, N-(3-carboxypropyl)-N-methylamino, 2-(3-hydroxypropyl)pyrrolidino, 4-hydroxymethylpiperidino, 4-(2-hydroxyethyl)piperidino, 4-(3-hydroxypropyl)piperidino, 4-(2-hydroxyethoxy)piperidino, 4-

(hydroxyacetamido)piperidino, 4-(2-hydroxyethoxymethyl)piperidino or 4-(2-hydroxyethyl)piperazino.

Claim 46 (New): The compound or pharmacologically acceptable salt thereof according to claim 45, wherein

R^1 is phenyl; or phenyl substituted with 1 to 3 groups selected from the group consisting of halogeno lower alkyl groups, lower alkoxy groups and hydroxyl groups and

R^3 is $-(CH_2)_m-CO-R^5$.

Claim 47 (New): The compound or pharmacologically acceptable salt thereof according to claim 46, wherein

R^1 is phenyl substituted with 1 to 3 groups selected from the group consisting of halogeno lower alkyl groups and lower alkoxy groups,

R^2 is 3,4-difluorophenyl or 3,4-dichlorophenyl,

R^3 is $-CH_2-CO-N(R^a)R^b$,

R^5 represents a group $-N(R^a)R^b$,

A is a carbonyl group,

B is a single bond, and

E is ethylene or trimethylene.

Claim 48 (New): The compound or pharmacologically acceptable salt thereof according to claim 47, wherein

R^1 is 3,5-bis(trifluoromethyl)phenyl or 3,4,5-trimethoxyphenyl

n is 1 or 2 and

R^3 is $-\text{CH}_2-\text{CO}-\text{N}(\text{CH}_3)-(\text{CH}_2)_4-\text{OH}$.

Claim 49 (New): The compound according to claim 1, designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{[(morpholin-1-yl)acetyl]oxy})indane-1,4'-piperidine.

Claim 50 (New): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{[(morpholin-1-yl)acetyl]oxy})indane-1,4'-piperidine.

Claim 51 (New): The compound according to claim 1, designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{2-[bis(2-hydroxyethyl)amino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 52 (New): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{2-[bis(2-hydroxyethyl)amino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 53 (New): The compound according to claim 1, designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{[N-(2-hydroxyethyl)-N-methylamino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 54 (New): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{[N-(2-hydroxyethyl)-N-methylamino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 55 (New): The compound according to claim 1, designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{2-[N-(2-hydroxyethyl)amino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 56 (New): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{2-[N-(2-hydroxyethyl)amino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 57 (New): The compound according to claim 1, designated 2-[((2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]-N-(4-hydroxybutyl)-N-methylacetamide.

Claim 58 (New): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 2-[((2S)-1'-{2-[(2R)-4-[3,5-bis(Trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]-N-(4-hydroxybutyl)-N-methylacetamide.

Claim 59 (New): The compound according to claim 1, designated 2-[((2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]-N-(3-hydroxypropyl)-N-methylacetamide.

Claim 60 (New): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 2-[(2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]-N-(3-hydroxypropyl)-N-methylacetamide.

Claim 61 (New): The compound according to claim 1, designated 2-(1-{[(2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]acetyl}piperidin-4-yl)ethanol.

Claim 62 (New): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 2-(1-{[(2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]acetyl}piperidin-4-yl)ethanol.

Claim 63 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R³ is -CO-R⁴.

Claim 64 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-\text{CO}-\text{O}-R^4$.

Claim 65 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-\text{CO}-\text{NH}-R^4$.

Claim 66 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-\text{CO}-\text{CH}_2-\text{N}(R^a)R^b$.

Claim 67 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-(\text{CH}_2)_m-\text{CO}-R^5$.

Claim 68 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-(\text{CH}_2)_m-R^5$.

Claim 69 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-\text{CO}-\text{NH}-\text{CO}-\text{N}(R^a)R^b$.

Claim 70 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-\text{CO}-\text{NH}-\text{SO}_2-\text{N}(R^a)R^b$.

Claim 71 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-\text{CO}-\text{NH}-\text{CO}-(\text{CH}_2)_m-\text{N}(\text{R}^a)\text{R}^b$.

Claim 72 (New): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-\text{CO}-\text{NH}_2$.